TabletsClinical Overview
Sorafenib Tablets (200mg) is an oral multi-kinase inhibitor targeting both tumor cell proliferation and tumor angiogenesis on the WHO Model List of Essential Medicines. It potently inhibits intracellular serine/threonine kinases in the RAF/MEK/ERK pathway (CRAF, BRAF, mutant V600E BRAF) and cell-surface receptor tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, FLT3, and RET. Indicated for unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and locally recurrent or metastatic progressive radioactive iodine-refractory differentiated thyroid carcinoma.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 400 mg (two 200 mg tablets) twice daily on an EMPTY STOMACH: at least 1 hour before or 2 hours after meals with a glass of water. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hand-foot skin reaction (palmar-plantar erythrodysesthesia in >30-40%), diarrhea, fatigue, alopecia, hypertension, weight loss, anorexia. Rare/Severe: Severe hypertension/hypertensive crisis, gastrointestinal perforation, cardiac ischemia/infarction, QT prolongation, and hemorrhage.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Hand-foot skin reaction is common; apply keratolytic urea creams and manage with dose modification. Routinely monitor blood pressure weekly during the first 6 weeks. Take on an empty stomach. Temporary discontinuation is recommended prior to major surgery due to impaired wound healing.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.